Cisatracurium Besylate Injection, USP is a clear solution supplied as follows:
Cisatracurium Besylate Injection, USP, 2 mg cisatracurium per mL, is supplied in the following:
| Unit of Sale | Concentration |
|---|---|
NDC 0409-1098-02 | 10 mg/5 mL |
Carton containing 10 Single-dose Vials | (2 mg/mL) |
NDC 0409-1208-01 | 20 mg/10 mL |
Carton containing 10 Multiple-dose Vials | (2 mg/mL) |
NOTE: 10 mL Multiple-dose vials contain 0.9% w/v benzyl alcohol as a preservative [see Warnings and Precautions (5.2)].
Cisatracurium Besylate Injection, USP, 10 mg cisatracurium per mL is supplied in the following:
| Unit of Sale | Concentration |
|---|---|
NDC 0409-1103-01 | 200 mg/20 mL |
Carton containing 10 Single-dose Vials | (10 mg/mL) |
Intended only for use in the ICU.
Discard unused portion of the 5 mL and 20 mL single-dose vials.
Storage
Cisatracurium Besylate Injection, USP should be refrigerated at 2°C to 8°C (36°F to 46°F) in the carton to preserve potency. Protect from light. DO NOT FREEZE. Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Cisatracurium Besylate Injection, USP within 21 days, even if re-refrigerated.
Cisatracurium Besylate Injection, USP is a clear solution supplied as follows:
Cisatracurium Besylate Injection, USP, 2 mg cisatracurium per mL, is supplied in the following:
| Unit of Sale | Concentration |
|---|---|
NDC 0409-1098-02 | 10 mg/5 mL |
Carton containing 10 Single-dose Vials | (2 mg/mL) |
NDC 0409-1208-01 | 20 mg/10 mL |
Carton containing 10 Multiple-dose Vials | (2 mg/mL) |
NOTE: 10 mL Multiple-dose vials contain 0.9% w/v benzyl alcohol as a preservative [see Warnings and Precautions (5.2)].
Cisatracurium Besylate Injection, USP, 10 mg cisatracurium per mL is supplied in the following:
| Unit of Sale | Concentration |
|---|---|
NDC 0409-1103-01 | 200 mg/20 mL |
Carton containing 10 Single-dose Vials | (10 mg/mL) |
Intended only for use in the ICU.
Discard unused portion of the 5 mL and 20 mL single-dose vials.
Storage
Cisatracurium Besylate Injection, USP should be refrigerated at 2°C to 8°C (36°F to 46°F) in the carton to preserve potency. Protect from light. DO NOT FREEZE. Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Cisatracurium Besylate Injection, USP within 21 days, even if re-refrigerated.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.